After seeing solid current value growth during most of the review period, dermatologicals is expected to see a decline in 2020, which can be attributed to COVID-19. However, the impact on the categories within dermatologicals is expected to be different.
Store-based retailers such as chemists/pharmacies and drugstores/parapharmacies are expected to remain the main distribution channels for dermatologicals in 2020, since consumers tend to seek advice from pharmacists in such outlets. All dermatologicals are readily available in these healthcare specialist retailers, but topical germicidals/antiseptics and antipruritics also can be obtained in more easily accessible channels, such as convenience stores.
Johnson & Johnson Indonesia is expected to maintain its lead in dermatologicals in value terms in 2020, with its Daktarin brand remaining the leading brand. It is expected to remain the leader in both topical antifungals (Daktarin) and nappy (diaper) rash treatments (Daktarin Diaper).
Although dermatologicals is expected to return to current value growth in 2021, the rate of increase is expected to be negligible. Even by the end of the forecast period, the growth rates seen in the review period are not expected to be achieved.
Despite the strong rise of nappy (diaper) rash treatments, topical antifungals is expected to remain the largest category within dermatologicals throughout the forecast period. Indonesia’s tropical climate, with its high humidity, makes rashes and scabies quite common in the country, particularly amongst people who live in unsanitary neighbourhoods.
Mahakam Beta Farma’s Betadine is expected to continue to dominate topical germicidals/antiseptics in 2020, as it has little competition in the country. Betadine is so well-known in Indonesia that Indonesians tend to ask for Betadine rather iodine when they go to chemists/pharmacies and other stores.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Medicated Skin Care industry in Indonesia with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Medicated Skin Care industry in Indonesia, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Medicated Skin Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page